Evaluation of Alirocumab Versus Ezetimibe on Top of Statin in Asia in High Cardiovascular Risk Patients With Hypercholesterolemia
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 615 participants.
Also called NCT02715726
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 615 participants
- Sponsor
- Registry
-
NCT02715726
-
- Other papers using this trial's data
- ODYSSEY EAST: Alirocumab efficacy and safety vs ezetimibe in high cardiovascular risk patients with hypercholesterolemia and on maximally tolerated statin in China, India, and Thailand
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- China, India, Thailand
- Registry status
- Completed
Technical summary
Registry record NCT02715726. Randomized; quadruple masking; primary purpose treatment. Start 2016-07-27 (actual); primary completion 2018-08-06 (actual). Results posted on 2019-09-30.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evaluation of Alirocumab Versus Ezetimibe on Top of Statin in Asia in High Cardiovascular Risk Patients With Hypercholesterolemia
- Acronym
- ODYSSEY EAST
- Condition
- Hypercholesterolemia
- Intervention (Drug)
- Alirocumab
- Intervention (Drug)
- Placebo for alirocumab
- Intervention (Drug)
- ezetimibe
- Intervention (Drug)
- placebo for ezetimibe
- Intervention (Drug)
- atorvastatin
- Intervention (Drug)
- rosuvastatin
- Intervention (Drug)
- simvastatin
- Lead sponsor
- Sanofi
- Collaborator
- Regeneron Pharmaceuticals
Record details
- Record id
cardio:ct-nct02715726- Content hash
cf5ab68fd3c8d0d55fb9b0ad57cd3abd83734bd9658d655b1f27d3727fa1573b